Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Idea Of The Day -- Ignore unavailable to you. Want to Upgrade?

To: Behrooz Rezai who wrote (20789)	10/5/1998 3:16:00 PM
From: Logistics	Read Replies (1) \| Respond to of 50167

HIV HIV HIV put out this news today and stock has not moved. ENMD put out similar news and stock moved 30 points 1 month later when NY Times picked up the news. BUYING HIV HERE!! AIDS Vaccine Effective in Animal Tests" "Animal Studies Published in Vaccine Show Promising Advancements" ..."Seventy-eight percent (78%) of the SCID mice given the blood from vaccinated individuals, were protected from HIV infection. Of the mice receiving the non-vaccinated control blood, only thirteen percent (13%) showed no evidence of infection, according to Dr. James Talmadge at the University of Nebraska Medical Center in Omaha, who performed the mouse study."... ..."These results provide evidence that HGP-30 may have worldwide applicability as an AIDS vaccine,'' Dr. Sarin said."... ..."In animal and human studies, CEL-SCI's vaccine has been shown to generate immune responses that recognize the major HIV subtypes, representing more than 90 percent of the world's AIDS cases. CEL-SCI's vaccine generated immune responses in animals which recognized peptides representing analogous regions of subtypes A, B, C, D and E. In humans, similar responses were found against peptides representing subtypes A, B, C and E."... biz.yahoo.com